Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Treasury Shares: 2009-2024

Historic Treasury Shares for Ligand Pharmaceuticals (LGND) over the last 4 years, with Dec 2013 value amounting to $42.3 million.

  • Ligand Pharmaceuticals' Treasury Shares changed negligibly% to $42.3 million in Q4 2013 from the same period last year, while for Dec 2013 it was $42.3 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $42.3 million for FY2013, which is negligibly% changed negligibly from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Treasury Shares of $42.3 million as of FY2013, which was down 0.00% from $42.3 million recorded in FY2012.
  • In the past 5 years, Ligand Pharmaceuticals' Treasury Shares registered a high of $934,079 during FY2020, and its lowest value of $264,143 during FY2021.
  • Moreover, its 3-year median value for Treasury Shares was $350,905 (2023), whereas its average is $379,077.
  • Data for Ligand Pharmaceuticals' Treasury Shares shows a peak YoY climbed of 0.13% (in 2011) over the last 5 years.
  • Yearly analysis of 4 years shows Ligand Pharmaceuticals' Treasury Shares stood at $42.2 million in 2010, then rose by 0.13% to $42.3 million in 2011, then remained steady at $42.3 million in 2012, then remained steady at $42.3 million in 2013.